Ontogeny of expression and glucocorticoid regulation of the arginine vasopressin gene in the rat hypothalamic paraventricular nucleus

Differential contribution of CBP:CREB binding to corticotropin-releasing hormone expression in the infant and adult hypothalamus

Corticotropin-releasing hormone (CRH) contributes crucially to the regulation of central and peripheral responses to stress. Because of the importance of a finely tuned stress system, CRH expression is tightly regulated in an organ- and brain region-specific manner. Thus, in the hypothalamus, CRH is constitutively expressed and this expression is further enhanced by stress; however, the underlying regulatory mechanisms are not fully understood. The regulatory region of the crh gene contains several elements, including the cyclic-AMP response element (CRE), and the role of the CRE interaction with the cyclic-AMP response element binding protein (CREB) in CRH expression has been a focus of intensive research. Notably, whereas thousands of genes contain a CRE, the functional regulation of gene expression by the CRE:CREB system is limited to ∼100 genes, and likely requires additional proteins. Here, we investigated the role of a member of the CREB complex, CREB binding protein (CBP), in basal and stress-induced CRH expression during development and in the adult. Using mice with a deficient CREB-binding site on CBP, we found that CBP:CREB interaction is necessary for normal basal CRH expression at the mRNA and protein level in the nine-day-old mouse, prior to onset of functional regulation of hypothalamic CRH expression by glucocorticoids. This interaction, which functions directly on crh or indirectly via regulation of other genes, was no longer required for maintenance of basal CRH expression levels in the adult. However, CBP:CREB binding contributed to stress-induced CRH expression in the adult, enabling rapid CRH synthesis in hypothalamus. CBP:CREB binding deficiency did not disrupt basal corticosterone plasma levels or acute stress-evoked corticosterone release. Because dysregulation of CRH expression occurs in stress-related disorders including depression, a full understanding of the complex regulation of this gene is important in both health and disease.

Magnocellular vasopressin system in ontogenesis: development and regulation

This review is devoted to the development, functional activity, and regulation of the magnocellular vasopressin (VP) system in ontogenesis. Magnocellular VP neurons originate in embryos from the neuroepithelium of the third ventricle and migrate first to the supraoptic nucleus and then to the paraventricular nucleus and accessory nuclei. The preproVP gene and synthesis are expressed simultaneously in the newly formed neurons either during migration or just after arrival in magnocellular nuclei. Still, a number of VP-immunoreactive neurons increase in immature mammals to prepuberty, which is explained by VP expression in the initially "silent" neurons, or by an increase of VP synthesis that makes a cell distinguishable by immunocytochemistry. An enzymatic processing of preproVP is slightly delayed compared to the onset of preproVP synthesis. Axons of magnocellular neurons reach the pituitary posterior lobe before or just after the neuron arrival in magnocellular nuclei. The mechanisms of VP release from the axon terminals are developed in immature animals over the perinatal period. The VP neurons begin to react to functional (osmotic) stimulation by increased synthesis of VP mRNA and VP in immature animals from the end of fetal life. A functional maturation of the VP system is under control by neural afferents, neuropeptides, and some hormones of endocrine glands. Namely, glucocorticoids, VP, catecholamines, glutamate, and opioids provide short-term or long-lasting effects on differentiating VP neurons. Most of the intercellular signals inhibit the specific phenotype expression of differentiating VP neurons: VP gene and synthesis in normal conditions, as well as TH gene and synthesis under functional stimulation.

Corticosterone differentially modulates expression of corticotropin releasing factor and arginine vasopressin mRNA in the hypothalamic paraventricular nucleus following either acute or repeated restraint stress

Exposing rats to repeated restraint stress induces well-characterized adaptations in the expression of either corticotropin-releasing factor (CRF) or arginine-vasopressin (AVP) mRNA in the parvocellular neurons of the hypothalamic paraventricular nucleus (PVN). The effects of regulating corticosterone levels on this adaptation was studied in male rats. In intact rats, acute restraint stress increased the expression of CRF mRNA whilst AVP mRNA expression was no different to control. Repeated exposure resulted in habituation of CRF expression, whereas AVP mRNA increased above that seen in either non stressed or acutely stressed animals. In adrenalectomised rats with replacement pellets of corticosterone that replicated blood levels approximating to the daily trough (mean levels 37--65 ng/mL), basal CRF expression levels were raised, but the response to acute stress was still observed. However, the habituation seen in normal animals that had been repeatedly stressed was prevented, so that CRF mRNA levels continued to be raised after repeated stress. By contrast, the AVP response to both acute and repeated stress was unaltered in these low-dose corticosterone-treated rats compared with controls. Higher dose pellets, which resulted in blood levels around those of the daily maximum (mean 118--141 ng/mL) had the opposite effects. There was no change compared to intact rats in the expression of CRF mRNA following either acute or repeated stress, but the expected increase in AVP following repeated restraint was prevented. These experiments show that corticosterone has important modulating effects on the adaptive pattern of both CRF and AVP mRNA expression in the parvocellular PVN. The 'set-point' of corticosterone differs; for CRF, experiencing higher levels is necessary for subsequent adaptation to repeated restraint to occur, whereas for AVP a return to lower levels is necessary to allow this peptide to respond to repeated stress.

Development of divergence in dopamine responsiveness in genetically selected rat lines is preceded by changes in pituitary-adrenal activity

Two pharmacogenetically selected Wistar rat lines have been used as a model for individual variability in behavioral and neuroendocrine responses. As a selection criterion the behavioral responsiveness for the dopamine agonist apomorphine was used, giving rise to the apomorphine-susceptible (apo-sus) and apomorphine-unsusceptible (apo-unsus) rat lines. This selection has been maintained over 16 generations. Recent studies have shown that adult rats of these selection lines also show pronounced differences in responsiveness of the hypothalamic-pituitary-adrenal (HPA) system. In this study we analyzed to what extent the divergence in dopamine phenotype and HPA responsiveness, as observed in adult rats, are linked to possible differences, within both systems, during early postnatal development. Therefore, we measured in neonatal female rats of 10 and 18 days of age several parameters of the dopamine and HPA system which show significant differences in adult rats. These include tyrosine hydroxylase (TH) and dopamine D1 and D2 receptor mRNA levels, which were determined within the nigrostriatal system since this system shows the most pronounced differences between adult rats of both selection lines. As indices of HPA activity we measured CRH mRNA, ACTH and total and free corticosterone plasma concentrations under basal conditions in the morning. Transcripts of the two types of corticosteroid receptors, mineralocorticoid (MR) and glucocorticoid (GR) receptor were measured in hippocampus and paraventricular nucleus. In 10-day-old rats all dopamine and HPA parameters were similar in rats of the two selection lines, except for GR mRNA in the parvocellular neurons of the paraventricular nucleus of the hypothalamus (PVN) of apo-sus rats, which was significantly higher than in apo-unsus rats. Eighteen-day-old apo-sus rats, however, showed significantly higher ACTH, comparable total corticosterone and a trend towards lower free corticosterone plasma levels. This HPA profile resembles the situation in adult apo-sus rats as compared with adult apo-unsus rats. Hippocampal GR mRNA expression and thymus weight were also higher in apo-sus rats. In addition, these rats showed an age-related increase in hippocampal MR mRNA expression, while in apo-unsus rats MR mRNA levels did not change between pnd 10 and 18. The measures of the nigrostriatal dopamine system at day 18 were still similar in rats of both lines. In conclusion, divergence in the dopamine systems of the two pharmacogenetically selected rat lines emerges subsequent to divergence in pituitary-adrenal activity.

Ontogenic development and distribution of mRNAs of chromogranin A and B, secretogranin II, p65 and synaptin/synaptophysin in rat brain

We have studied by in situ hybridization the mRNA levels of several constituents of transmitter storing vesicles during ontogenic development of rat brain. The following vesicle components were investigated: chromogranin A and B and secretogranin II, representing secretory peptides of large dense core vesicles, and the membrane proteins p65 and synaptin/synaptophysin which are found in both large and small synaptic vesicles but are concentrated in the latter ones. Several ontogenic patterns were observed: concomitant increases of most or all mRNAs in certain brain regions, e.g. in the thalamic nuclei at gestational day 18 or in the cortex at postnatal day 6. For some areas selective increases for the various chromogranin mRNAs occurred, thus throughout development the substantia nigra compacta contained only the chromogranin B mRNA, whereas the lateral and medial geniculate nuclei and the medial tuberal nucleus expressed only secretogranin II mRNA. In the paraventricular hypothalamic nucleus, secretogranin II mRNA declined at P1 and then increased again. In the intermediate cortex there was a rather selective appearance of a high level of chromogranin A mRNA already at gestational day 16. In general the mRNAs for the membrane components become detectable by in situ hybridization together with the chromogranin mRNA, however, in the claustrum a high level of the p65 mRNA is present already at gestational day 16 whereas the chromogranin mRNA only appears at day 20. In some nuclei there was also a differential expression of the membrane components with e.g. the synaptophysin mRNA being present without any concomitant appearance of p65. These results establish that the ontogenic development of the investigated components in many brain areas simply indicate the starting point of biosynthesis of both types of vesicles finally leading to functional synapses. In those cases where a selective dissociation in the biosynthesis of these components occurs, a functional relevance of one component for a certain stage of development might be postulated. Since these data define the time of onset of vesicle biosynthesis in the various brain regions, future studies on single components of these vesicles can be interpreted in the context of the present findings.